The cause of Alzheimer's disease is not fully understood and the blood-brain barrier restricts drug efficacy are two main factors that hamper research. Stem cell-based therapy has been seen as an effective, secure, and creative therapeutic solution to overcoming AD because of AD's multifactorial...
Alzheimer’s disease: the right drug, the right time. Science 362, 1250–1251 (2018). CAS PubMed Google Scholar Herrup, K. The case for rejecting the amyloid cascade hypothesis. Nat. Neurosci. 18, 794–799 (2015). CAS PubMed Google Scholar Zlokovic, B. V. et al. Vascular ...
When the US Food and Drug Administration (FDA) approved biotechnology firm Biogen’s drug for Alzheimer’s disease in June, regulators hoped to usher in a new era of treatment for the neurodegenerative condition. But the decision followed an independent advisory committee’s near-unanimous vote to...
Alzheimer’s disease: the right drug, the right time. Science 362, 1250–1251 (2018). CAS PubMed Google Scholar Herrup, K. The case for rejecting the amyloid cascade hypothesis. Nat. Neurosci. 18, 794–799 (2015). CAS PubMed Google Scholar Zlokovic, B. V. et al. Vascular ...
APOE, apolipoprotein E; DMT, disease-modifying therapy. (Figure © J Cummings; M de la Flor, PhD, Illustrator). TABLE 2. Agents in Phase 2 of Alzheimer's disease drug development (ClinicalTrials.gov accessed January 1, 2023). AgentTherapeutic purposeCADRO targetMechanism of actionClinical ...
Alzheimer's disease (AD) presents the largest unmet need in neurology. This article provides an overview of the rationale and the issues that underlie the different strategies for drug discovery in AD, with a focus on approaches aimed at slowing or halti
Over the last 15 years, researchers have found a significant association between vascular diseases such as hypertension, atherosclerosis, type 2 diabetes, hyperlipidemia, and heart disease and an increased risk of Alzheimer's disease. In theJournal of Alzheimer's Disease, leading experts provide a co...
s disease [21,22]. In the past ten years, more than 50% of the Alzheimer’s disease drug pipeline has included immunotherapies or oral small molecules, with the main disease-modifying drug targets being amyloid β and tau protein [22]. In the past four years, the drug pipeline has ...
U.S. health officials on Friday approved aclosely watchedAlzheimer's drug that modestly slows the brain-robbing disease, albeit with potential safety risks that patients and their doctors will have to carefully weigh. The drug, Leqembi, is the first that's been convincingly shown to slow the ...
Alzheimer's disease is a chronic illness with long preclinical and prodromal phases (20 years) and an average clinical duration of 8–10 years. The disease has an estimated prevalence of 10–30% in the population >65 years of age with an incidence of